Karolinska Development Closes Fully Subscribed New S... (nska Development hasbeen able to demonst...)

Karolinska Development Closes Fully Subscribed New Share Issue

Date:1/8/2009

nska Development has been able to demonstrate the robustness of the business model and the significant growth potential in the company," says Martin Nilsson, CEO EFG Bank.

A prospectus of this offering has been filed with the Swedish Financial Supervisory Authority, Finansinspektionen

About Karolinska Development

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future.

Karolinska Development's office is located at the Karolinska Institute Science Park, Solna/Stockholm Sweden http://www.karolinskadevelopment.com

About EFG Bank AB

EFG Bank is a subsidiary of EFG International and a member of EFG Group, the third largest banking group in Switzerland by Tier-1 Capital. In Sweden and in other Nordic countries, EFG Bank offers asset management services and financial investments to institutions, private individuals and financial advisors. EFG Bank is headquartered in Stockholm, Sweden. http://www.efgbank.se

EFG International is a global banking group offering services within private banking and asset management. EFG International operates in 55 locations in over 30 countries. It is headquartered in Zurich and has circa 2,200 employees. EFG International's registered shares (EFGN) are listed on the SIX Swiss Exch
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
4. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Global Experts Explore Entire Spectrum of Aids Vaccine Development
7. Vical Names Andrew de Guttadauro Vice President, Corporate Development
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. SemBioSys updates Apo AI development program
10. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals

Post Your Comments:

Karolinska Development Closes Fully Subscribed New S...(nska Development hasbeen able to demonst...)